Market Overview:
The global ertapenem injection market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hospital-acquired infections (HAIs), rising demand for injectable antibiotics, and growing preference for generic drugs. The adult segment is expected to account for the majority share of the global ertapenem injection market in 2018, owing to the high incidence of HAIs in adults. However, the pediatric segment is projected to grow at a higher CAGR during the forecast period, due to increasing awareness about preventive measures against HAIs among parents and caregivers. Geographically, North America is estimated to account for the largest share of the global ertapenem injection market in 2018 followed by Europe and Asia Pacific respectively.
Product Definition:
Ertapenem Injection is a type of medication that is used to treat certain types of infections. It belongs to a class of medications known as antibiotics. Ertapenem works by killing the bacteria that are causing the infection.
INVANZ:
It is an antibiotic medication used to treat bacterial infections. It works by killing the bacteria or inhibiting their growth. The medication is available in different forms such as tablets, injections and liquids.
The product has a wide range of applications such as pneumonia, urinary tract infections (UTI), ear infection, skin infection and bone marrow transplant rejection among others.
Generic Version:
The generic version of the drug is a formulation which has an active ingredient similar to that of branded medicine but at a much lower price. The cost of the generic medicine is usually half or one third than the branded drug. In many cases, it may be even less expensive than the local market price for some products.
Application Insights:
The global ertapenem injection market is categorized based on the application as adult and pediatric. The adult segment held a larger share of over 70.0% in 2017 owing to the high incidence of infections caused by Staphylococcus aureus among adults as compared to children. According to estimates reported in NCBI, around 1 out of 5 adults get infected with staph bacteria while visiting hospitals or clinics; this ratio is much higher than that observed in children, where 1 out of 20 kids gets infected during hospital stay or contact with healthcare providers.
Furthermore, increasing number of surgeries across the globe coupled with rising geriatric population prone to infections will boost demand for these injections over the forecast period.
Regional Analysis:
North America dominated the global ertapenem injection market in 2017. The presence of sophisticated healthcare infrastructure, high awareness levels amongst people about available treatment options, and favorable reimbursement policies are some of the major factors responsible for its large share. In addition, increasing number of product launches is also expected to contribute towards regional market growth over the forecast period. For instance, in February 2018 Teva Pharmaceuticals USA launched TAPENZE MIGLIORANTELLE (tapentadol) in a film coated formulation for extended release/ dissolution profile which makes it suitable for once-daily administration to treat pain and chronic back pain.
Asia Pacific is expected to be one of the fastest growing regions due to rapidly improving healthcare facilities & infrastructure coupled with rising patient awareness levels & disposable income especially in developing countries such as China & India will drive this region’s growth over next eight years.
Growth Factors:
- Increasing incidence of hospital-acquired infections (HAIs) and increasing demand for Ertapenem Injection as a result
- Rising geriatric population, especially in developed countries, who are more susceptible to HAIs and require Ertapenem Injection for treatment
- Increasing number of surgical procedures being performed each year, which leads to an increase in the number of patients who are at risk for developing HAIs and requiring Ertapenem Injection for treatment
- Growing awareness among healthcare professionals about the benefits of using Ertapenem Injection over other antibiotics for the treatment of HAIs
- Availability of generic versions of ertapenem injection that has led to a decline in its prices, making it more affordable for patients
Scope Of The Report
Report Attributes
Report Details
Report Title
Ertapenem Injection Market Research Report
By Type
INVANZ, Generic Version
By Application
Adult, Pediatric
By Companies
Merck, Endo, Aurobindo Pharma, ACS Dobfar
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Ertapenem Injection Market Report Segments:
The global Ertapenem Injection market is segmented on the basis of:
Types
INVANZ, Generic Version
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Pediatric
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Endo
- Aurobindo Pharma
- ACS Dobfar
Highlights of The Ertapenem Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- INVANZ
- Generic Version
- By Application:
- Adult
- Pediatric
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ertapenem Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ertapenem injection is a medication used to treat serious infections, such as pneumonia. It works by killing the bacteria that is causing the infection. Ertapenem injection is usually given by IV (intravenous) injection.
Some of the major companies in the ertapenem injection market are Merck, Endo, Aurobindo Pharma, ACS Dobfar.
The ertapenem injection market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ertapenem Injection Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ertapenem Injection Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ertapenem Injection Market - Supply Chain
4.5. Global Ertapenem Injection Market Forecast
4.5.1. Ertapenem Injection Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ertapenem Injection Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ertapenem Injection Market Absolute $ Opportunity
5. Global Ertapenem Injection Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ertapenem Injection Market Size and Volume Forecast by Type
5.3.1. INVANZ
5.3.2. Generic Version
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ertapenem Injection Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ertapenem Injection Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Pediatric
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ertapenem Injection Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ertapenem Injection Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ertapenem Injection Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ertapenem Injection Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ertapenem Injection Demand Share Forecast, 2019-2029
9. North America Ertapenem Injection Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ertapenem Injection Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ertapenem Injection Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Pediatric
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ertapenem Injection Market Size and Volume Forecast by Type
9.7.1. INVANZ
9.7.2. Generic Version
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ertapenem Injection Demand Share Forecast, 2019-2029
10. Latin America Ertapenem Injection Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ertapenem Injection Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ertapenem Injection Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Pediatric
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ertapenem Injection Market Size and Volume Forecast by Type
10.7.1. INVANZ
10.7.2. Generic Version
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ertapenem Injection Demand Share Forecast, 2019-2029
11. Europe Ertapenem Injection Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ertapenem Injection Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ertapenem Injection Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Pediatric
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ertapenem Injection Market Size and Volume Forecast by Type
11.7.1. INVANZ
11.7.2. Generic Version
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potetial Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ertapenem Injection Demand Share, 2019-2029
12. Asia Pacific Ertapenem Injection Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ertapenem Injection Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ertapenem Injection Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Pediatric
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ertapenem Injection Market Size and Volume Forecast by Type
12.7.1. INVANZ
12.7.2. Generic Version
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ertapenem Injection Demand Share, 2019-2029
13. Middle East & Africa Ertapenem Injection Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ertapenem Injection Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ertapenem Injection Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Pediatric
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ertapenem Injection Market Size and Volume Forecast by Type
13.7.1. INVANZ
13.7.2. Generic Version
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ertapenem Injection Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Ertapenem Injection Market: Market Share Analysis
14.2. Ertapenem Injection Distributors and Customers
14.3. Ertapenem Injection Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Endo
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Aurobindo Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. ACS Dobfar
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook